ArticleJournal of enzyme inhibition and medicinal chemistry2020
Design, synthesis and biological evaluation of edaravone derivatives bearing the
Article in Journal of enzyme inhibition and medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Evaluation of antioxidant and anti-inflammatory potential andJournal of enzyme inhibition and medicinal chemistry · 2025Article
- Recent developments in the design of functional derivatives of edaravone and exploration of their antioxidant activities.Molecular diversity · 2025Review
- Synthetic and semi-synthetic antioxidants in medicine and food industry: a review.Frontiers in pharmacology · 2025Review
- Computational Approaches for Multitarget Drug Design in Alzheimer's Disease: A Comprehensive Review.Current medicinal chemistry · 2025Review
- Isoindolinedione-Benzamide Pyridinium Derivatives for Targeting Alzheimer's Disease.ACS omega · 2024Article
- Synthesis, Characterization and Assessment of Antioxidant and Melanogenic Inhibitory Properties of Edaravone Derivatives.Antioxidants (Basel, Switzerland) · 2024Article
- Pyrazolone-type compounds (part II):RSC advances · 2023Article
- Pyrazoline Containing Compounds as Therapeutic Targets for Neurodegenerative Disorders.ACS omega · 2022Review
- Discovery of Guanidine Derivatives fromMolecules (Basel, Switzerland) · 2021Article
- Current Approaches and Tools Used in Drug Development against Parkinson's Disease.Biomolecules · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A series of multi-target directed edaravone derivatives bearing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.